Improved GVHD-free relapse-free survival when rATG/ATLG is used in allo-HCT from matched sibling donors: an EBMT registry study by the Transplant Complications Working Party
The EBMT recommends rabbit anti-thymocyte or anti-T-lymphocyte globulin (rATG/ATLG) as GVHD prophylaxis in matched sibling donor (MSD) allogeneic hematopoietic cell transplantation (allo-HCT). However, discrepancies between recommendations and clinical practice were reflected in the EBMT survey. The...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
11 September 2025
|
| In: |
Bone marrow transplantation
Year: 2025, Jahrgang: 60, Heft: 12, Pages: 1574-1583 |
| ISSN: | 1476-5365 |
| DOI: | 10.1038/s41409-025-02692-1 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1038/s41409-025-02692-1 Verlag, lizenzpflichtig, Volltext: https://www.nature.com/articles/s41409-025-02692-1 
|
| Verfasserangaben: | Agnieszka Piekarska, Mouad Abouqateb, William Boreland, Christophe Peczynski, Jan Maciej Zaucha, Nicolaus Kröger, Robert Zeiser, Fabio Ciceri, Thomas Schroeder, Thomas Luft, Jakob Passweg, Desiree Kunadt, Matthias Stelljes, Igor Wolfgang Blau, Uwe Platzbecker, Ibrahim Yakoub-Agha, Didier Blaise, Anna Maria Raiola, Johanna Tischer, Eva Maria Wagner-Drouet, Julia Winkler, Christoph Schmid, Gerald Wulf, Matthias Edinger, Johan Maertens, Friedrich Stölzel, Jan Vydra, Pavel Zak, Ivan Moiseev, Hélène Schoemans, Olaf Penack and Zinaida Peric |
MARC
| LEADER | 00000naa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1951324021 | ||
| 003 | DE-627 | ||
| 005 | 20260206084859.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 260206s2025 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41409-025-02692-1 |2 doi | |
| 035 | |a (DE-627)1951324021 | ||
| 035 | |a (DE-599)KXP1951324021 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Piekarska, Agnieszka |e VerfasserIn |0 (DE-588)1389133028 |0 (DE-627)1951324781 |4 aut | |
| 245 | 1 | 0 | |a Improved GVHD-free relapse-free survival when rATG/ATLG is used in allo-HCT from matched sibling donors |b an EBMT registry study by the Transplant Complications Working Party |c Agnieszka Piekarska, Mouad Abouqateb, William Boreland, Christophe Peczynski, Jan Maciej Zaucha, Nicolaus Kröger, Robert Zeiser, Fabio Ciceri, Thomas Schroeder, Thomas Luft, Jakob Passweg, Desiree Kunadt, Matthias Stelljes, Igor Wolfgang Blau, Uwe Platzbecker, Ibrahim Yakoub-Agha, Didier Blaise, Anna Maria Raiola, Johanna Tischer, Eva Maria Wagner-Drouet, Julia Winkler, Christoph Schmid, Gerald Wulf, Matthias Edinger, Johan Maertens, Friedrich Stölzel, Jan Vydra, Pavel Zak, Ivan Moiseev, Hélène Schoemans, Olaf Penack and Zinaida Peric |
| 264 | 1 | |c 11 September 2025 | |
| 300 | |b Graph. Darst. | ||
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 06.02.2026 | ||
| 520 | |a The EBMT recommends rabbit anti-thymocyte or anti-T-lymphocyte globulin (rATG/ATLG) as GVHD prophylaxis in matched sibling donor (MSD) allogeneic hematopoietic cell transplantation (allo-HCT). However, discrepancies between recommendations and clinical practice were reflected in the EBMT survey. Therefore, we performed retrospective EBMT registry analysis from 2014 to 2021 to reinforce the real-world evidence context of rATG/ATLG impact on post-transplantation outcomes. This study included 11,420 adult patients (non-ATG n = 7680 and ATG n = 3740) with hematological malignancies after the first allo-HCT from peripheral blood. Use of ATG was associated with a reduced risk of aGVHD II-IV (Day +100: non-ATG vs ATG, 27.6% vs. 21.6%; adjusted HR 0.7, p < 0.001) and cGVHD (2-year: non-ATG vs ATG, 48.9% vs 30%; adjusted HR 0.45, p < 0.001), improved OS (2-year: 62.9% vs 63.3%; adjusted HR 0.89, p = 0.009), reduced NRM (2-year: 16% vs 12.5%; adjusted HR 0.63, p < 0.001), and higher GRFS (2-year: 32.2% vs 40.7%; adjusted HR 0.72, p < 0.001). While RI was higher in the ATG group (2-year: non-ATG vs ATG, 30.2% vs 34.7%; adjusted HR 1.22, p < 0.001) it did not translate into a significantly lower PFS (2-year: 53.9% vs 52.8%; adjusted HR not significant). Overall, outcomes were favorable for the intermediate rATG/ATLG dose ranges compared to the low and high dose ranges. Administration of rATG/ATLG improved outcomes in MSD allo-HCT recipients, supporting the EBMT recommendation for its use. | ||
| 650 | 4 | |a Risk factors | |
| 650 | 4 | |a Stem-cell research | |
| 700 | 1 | |a Abouqateb, Mouad |e VerfasserIn |4 aut | |
| 700 | 1 | |a Boreland, William |e VerfasserIn |4 aut | |
| 700 | 1 | |a Peczynski, Christophe |e VerfasserIn |4 aut | |
| 700 | 1 | |a Zaucha, Jan Maciej |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kröger, Nicolaus |e VerfasserIn |4 aut | |
| 700 | 1 | |a Zeiser, Robert |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ciceri, Fabio |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schroeder, Thomas |e VerfasserIn |4 aut | |
| 700 | 1 | |a Luft, Thomas |e VerfasserIn |0 (DE-588)1078976309 |0 (DE-627)839996969 |0 (DE-576)452120659 |4 aut | |
| 700 | 1 | |a Passweg, Jakob |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kunadt, Desiree |e VerfasserIn |4 aut | |
| 700 | 1 | |a Stelljes, Matthias |e VerfasserIn |4 aut | |
| 700 | 1 | |a Blau, Igor Wolfgang |e VerfasserIn |4 aut | |
| 700 | 1 | |a Platzbecker, Uwe |e VerfasserIn |4 aut | |
| 700 | 1 | |a Yakoub-Agha, Ibrahim |e VerfasserIn |4 aut | |
| 700 | 1 | |a Blaise, Didier |e VerfasserIn |4 aut | |
| 700 | 1 | |a Raiola, Anna Maria |e VerfasserIn |4 aut | |
| 700 | 1 | |a Tischer, Johanna |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wagner-Drouet, Eva Maria |e VerfasserIn |4 aut | |
| 700 | 1 | |a Winkler, Julia |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schmid, Christoph |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wulf, Gerald |e VerfasserIn |4 aut | |
| 700 | 1 | |a Edinger, Matthias |e VerfasserIn |4 aut | |
| 700 | 1 | |a Maertens, Johan |e VerfasserIn |4 aut | |
| 700 | 1 | |a Stölzel, Friedrich |e VerfasserIn |4 aut | |
| 700 | 1 | |a Vydra, Jan |e VerfasserIn |4 aut | |
| 700 | 1 | |a Zak, Pavel |e VerfasserIn |4 aut | |
| 700 | 1 | |a Moiseev, Ivan |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schoemans, Hélène |e VerfasserIn |4 aut | |
| 700 | 1 | |a Penack, Olaf |e VerfasserIn |4 aut | |
| 700 | 1 | |a Peric, Zinaida |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Bone marrow transplantation |d London : Springer Nature, 1997 |g 60(2025), 12, Seite 1574-1583 |h Online-Ressource |w (DE-627)320433366 |w (DE-600)2004030-1 |w (DE-576)091012996 |x 1476-5365 |7 nnas |a Improved GVHD-free relapse-free survival when rATG/ATLG is used in allo-HCT from matched sibling donors an EBMT registry study by the Transplant Complications Working Party |
| 773 | 1 | 8 | |g volume:60 |g year:2025 |g number:12 |g pages:1574-1583 |g extent:10 |a Improved GVHD-free relapse-free survival when rATG/ATLG is used in allo-HCT from matched sibling donors an EBMT registry study by the Transplant Complications Working Party |
| 856 | 4 | 0 | |u https://doi.org/10.1038/s41409-025-02692-1 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |7 1 |
| 856 | 4 | 0 | |u https://www.nature.com/articles/s41409-025-02692-1 |x Verlag |z lizenzpflichtig |3 Volltext |7 1 |
| 951 | |a AR | ||
| 992 | |a 20260206 | ||
| 993 | |a Article | ||
| 994 | |a 2025 | ||
| 998 | |g 1078976309 |a Luft, Thomas |m 1078976309:Luft, Thomas |d 910000 |d 910100 |d 50000 |e 910000PL1078976309 |e 910100PL1078976309 |e 50000PL1078976309 |k 0/910000/ |k 1/910000/910100/ |k 0/50000/ |p 10 | ||
| 999 | |a KXP-PPN1951324021 |e 4877606270 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"relHost":[{"id":{"eki":["320433366"],"issn":["1476-5365"],"zdb":["2004030-1"]},"part":{"issue":"12","extent":"10","volume":"60","year":"2025","text":"60(2025), 12, Seite 1574-1583","pages":"1574-1583"},"origin":[{"dateIssuedDisp":"1997-","dateIssuedKey":"1997","publisherPlace":"London ; Basingstoke ; London","publisher":"Springer Nature ; Macmillan ; Nature Publishing Group"}],"disp":"Improved GVHD-free relapse-free survival when rATG/ATLG is used in allo-HCT from matched sibling donors an EBMT registry study by the Transplant Complications Working PartyBone marrow transplantation","title":[{"title":"Bone marrow transplantation","title_sort":"Bone marrow transplantation"}],"pubHistory":["Nachgewiesen 19.1997 -"],"language":["eng"],"type":{"bibl":"periodical","media":"Online-Ressource"},"physDesc":[{"extent":"Online-Ressource"}],"recId":"320433366","note":["Gesehen am 17.01.25"]}],"physDesc":[{"noteIll":"Graph. Darst.","extent":"10 S."}],"recId":"1951324021","note":["Gesehen am 06.02.2026"],"language":["eng"],"origin":[{"dateIssuedKey":"2025","dateIssuedDisp":"11 September 2025"}],"person":[{"role":"aut","display":"Piekarska, Agnieszka","family":"Piekarska","given":"Agnieszka"},{"family":"Abouqateb","role":"aut","display":"Abouqateb, Mouad","given":"Mouad"},{"role":"aut","display":"Boreland, William","family":"Boreland","given":"William"},{"given":"Christophe","family":"Peczynski","display":"Peczynski, Christophe","role":"aut"},{"given":"Jan Maciej","display":"Zaucha, Jan Maciej","role":"aut","family":"Zaucha"},{"given":"Nicolaus","family":"Kröger","display":"Kröger, Nicolaus","role":"aut"},{"given":"Robert","family":"Zeiser","role":"aut","display":"Zeiser, Robert"},{"family":"Ciceri","display":"Ciceri, Fabio","role":"aut","given":"Fabio"},{"family":"Schroeder","role":"aut","display":"Schroeder, Thomas","given":"Thomas"},{"given":"Thomas","family":"Luft","display":"Luft, Thomas","role":"aut"},{"given":"Jakob","family":"Passweg","display":"Passweg, Jakob","role":"aut"},{"given":"Desiree","display":"Kunadt, Desiree","role":"aut","family":"Kunadt"},{"given":"Matthias","display":"Stelljes, Matthias","role":"aut","family":"Stelljes"},{"given":"Igor Wolfgang","family":"Blau","role":"aut","display":"Blau, Igor Wolfgang"},{"given":"Uwe","display":"Platzbecker, Uwe","role":"aut","family":"Platzbecker"},{"given":"Ibrahim","family":"Yakoub-Agha","display":"Yakoub-Agha, Ibrahim","role":"aut"},{"given":"Didier","family":"Blaise","display":"Blaise, Didier","role":"aut"},{"role":"aut","display":"Raiola, Anna Maria","family":"Raiola","given":"Anna Maria"},{"display":"Tischer, Johanna","role":"aut","family":"Tischer","given":"Johanna"},{"given":"Eva Maria","family":"Wagner-Drouet","role":"aut","display":"Wagner-Drouet, Eva Maria"},{"given":"Julia","family":"Winkler","display":"Winkler, Julia","role":"aut"},{"role":"aut","display":"Schmid, Christoph","family":"Schmid","given":"Christoph"},{"given":"Gerald","family":"Wulf","role":"aut","display":"Wulf, Gerald"},{"family":"Edinger","role":"aut","display":"Edinger, Matthias","given":"Matthias"},{"role":"aut","display":"Maertens, Johan","family":"Maertens","given":"Johan"},{"given":"Friedrich","role":"aut","display":"Stölzel, Friedrich","family":"Stölzel"},{"given":"Jan","display":"Vydra, Jan","role":"aut","family":"Vydra"},{"given":"Pavel","family":"Zak","display":"Zak, Pavel","role":"aut"},{"given":"Ivan","family":"Moiseev","role":"aut","display":"Moiseev, Ivan"},{"display":"Schoemans, Hélène","role":"aut","family":"Schoemans","given":"Hélène"},{"given":"Olaf","family":"Penack","role":"aut","display":"Penack, Olaf"},{"family":"Peric","display":"Peric, Zinaida","role":"aut","given":"Zinaida"}],"id":{"doi":["10.1038/s41409-025-02692-1"],"eki":["1951324021"]},"type":{"media":"Online-Ressource","bibl":"article-journal"},"name":{"displayForm":["Agnieszka Piekarska, Mouad Abouqateb, William Boreland, Christophe Peczynski, Jan Maciej Zaucha, Nicolaus Kröger, Robert Zeiser, Fabio Ciceri, Thomas Schroeder, Thomas Luft, Jakob Passweg, Desiree Kunadt, Matthias Stelljes, Igor Wolfgang Blau, Uwe Platzbecker, Ibrahim Yakoub-Agha, Didier Blaise, Anna Maria Raiola, Johanna Tischer, Eva Maria Wagner-Drouet, Julia Winkler, Christoph Schmid, Gerald Wulf, Matthias Edinger, Johan Maertens, Friedrich Stölzel, Jan Vydra, Pavel Zak, Ivan Moiseev, Hélène Schoemans, Olaf Penack and Zinaida Peric"]},"title":[{"title":"Improved GVHD-free relapse-free survival when rATG/ATLG is used in allo-HCT from matched sibling donors","title_sort":"Improved GVHD-free relapse-free survival when rATG/ATLG is used in allo-HCT from matched sibling donors","subtitle":"an EBMT registry study by the Transplant Complications Working Party"}]} | ||
| SRT | |a PIEKARSKAAIMPROVEDGV1120 | ||